Frontiers in Psychiatry,
Journal Year:
2022,
Volume and Issue:
13
Published: Dec. 6, 2022
Although
global
rates
of
suicide
have
dropped
in
the
last
30
years,
youth
low-
and
middle-income
countries
(LMICs)
continue
to
be
highly
represented
statistics
yet
underrepresented
research.
In
this
review
we
present
epidemiology
suicide,
suicidal
ideation,
attempts
among
LMICs.
We
also
describe
population-level
(attitudes
toward
socioeconomic,
societal
factors)
individual-level
clinical
psychosocial
risk
factors,
highlighting
specific
considerations
pertaining
These
factors
within
population
can
inform
how
multi-level
prevention
strategies
may
targeted
meet
their
needs.
Prevention
intervention
relying
on
stepped-care
framework
focusing
population-,
community-,
individual
level
targets
while
considering
locally-
culturally
relevant
practices
are
key
addition,
systemic
approaches
favoring
school-based
family-based
interventions
important
youth.
Cross-culturally
adapted
multimodal
targeting
heterogeneity
that
exists
healthcare
systems,
rates,
these
should
accorded
a
high
priority
reduce
burden
World Psychiatry,
Journal Year:
2023,
Volume and Issue:
22(3), P. 394 - 412
Published: Sept. 15, 2023
Treatment-resistant
depression
(TRD)
is
common
and
associated
with
multiple
serious
public
health
implications.
A
consensus
definition
of
TRD
demonstrated
predictive
utility
in
terms
clinical
decision-making
outcomes
does
not
currently
exist.
Instead,
a
plethora
definitions
have
been
proposed,
which
vary
significantly
their
conceptual
framework.
The
absence
hampers
precise
estimates
the
prevalence
TRD,
also
belies
efforts
to
identify
risk
factors,
prevention
opportunities,
effective
interventions.
In
addition,
it
results
heterogeneity
practice
decision-making,
adversely
affecting
quality
care.
US
Food
Drug
Administration
(FDA)
European
Medicines
Agency
(EMA)
adopted
most
used
(i.e.,
inadequate
response
minimum
two
antidepressants
despite
adequacy
treatment
trial
adherence
treatment).
It
estimated
that
at
least
30%
persons
meet
this
definition.
significant
percentage
are
actually
pseudo-resistant
(e.g.,
due
inadequacy
trials
or
non-adherence
Although
sociodemographic,
clinical,
contextual
factors
known
negatively
moderate
depression,
very
few
regarded
as
non-response
across
modalities
treatment.
Intravenous
ketamine
intranasal
esketamine
(co-administered
an
antidepressant)
established
efficacious
management
TRD.
Some
second-generation
antipsychotics
aripiprazole,
brexpiprazole,
cariprazine,
quetiapine
XR)
proven
adjunctive
treatments
partial
responders,
but
only
olanzapine-fluoxetine
combination
has
studied
FDA-defined
Repetitive
transcranial
magnetic
stimulation
(TMS)
FDA-approved
for
individuals
accelerated
theta-burst
TMS
recently
showing
efficacy.
Electroconvulsive
therapy
acute
maintenance
intervention
preliminary
evidence
suggesting
non-inferiority
intravenous
ketamine.
Evidence
extending
antidepressant
trial,
medication
switching
combining
mixed.
Manual-based
psychotherapies
on
own
offer
symptomatic
relief
when
added
conventional
antidepressants.
Digital
therapeutics
under
study
represent
potential
future
vista
population.
Evidence-Based Mental Health,
Journal Year:
2022,
Volume and Issue:
25(4), P. 148 - 155
Published: Sept. 26, 2022
Question
Effective
prevention
of
suicide
requires
a
comprehensive
understanding
risk
factors.
Study
selection
and
analysis
Five
databases
were
systematically
searched
to
identify
psychological
autopsy
studies
(published
up
February
2022)
that
reported
on
factors
for
mortality
among
adults
in
the
general
population.
Effect
sizes
pooled
as
odds
ratios
(ORs)
using
random-effects
models
each
factor
examined
at
least
three
independent
samples.
Findings
A
total
37
case–control
from
23
countries
included,
providing
data
40
5633
cases
7101
controls.
The
magnitude
effect
varied
substantially
both
between
within
domains.
Clinical
had
strongest
associations
with
suicide,
including
any
mental
disorder
(OR=13.1,
95%
CI
9.9
17.4)
history
self-harm
(OR=10.1,
6.6
15.6).
By
comparison,
smaller
other
domains
relating
sociodemographic
status,
family
history,
adverse
life
events
(OR
range
2–5).
Conclusions
wide
predisposing
precipitating
are
associated
population,
but
clear
differences
their
relative
strength.
PROSPERO
registration
number
CRD42021232878.
JAMA Network Open,
Journal Year:
2021,
Volume and Issue:
4(6), P. e2113513 - e2113513
Published: June 14, 2021
Importance
Disparities
by
sex
and
racial/ethnic
group
in
suicide
death
rates
are
present
US
adolescents.
Whether
disparities
extend
to
groups
targeted
for
prevention
efforts,
namely,
those
with
suicidal
ideation
or
nonfatal
attempts,
is
unknown.
Objective
To
examine
differences
temporal
trends
between
attempts
adolescents
from
1991
through
2019
race/ethnicity
subgroups.
Design,
Setting,
Participants
A
cross-sectional
analysis
of
the
national
Youth
Risk
Behavior
Survey,
weighted
represent
2019,
included
183
563
high-school
students
grades
9
12.
Data
were
analyzed
September
16,
2020,
April
12,
2021.
Survey-weighted
prevalence
estimates,
annual
percentage
changes
(APCs)
average
APC
survey-weighted
constructed
self-reported
ideation,
plan,
each
survey
(non-Hispanic
White,
non-Hispanic
Black,
Hispanic,
Asian
Pacific
Islander
Native
Hawaiian,
American
Indian/Alaska
Native),
their
(sex
×
race/ethnicity).
Results
In
(unweighted)
(mean
[SD]
age,
16.07
[1.23]
years;
94
282
females
[weighted
percentage,
49.4%;
95%
CI,
48.8%-50.1%]),
decreased
(from
19.4%
15.8%;
0.7%-0.9%),
whereas
increased
7.3%
8.9%;
1.0%-1.4%).
Joinpoint
regression
indicated
a
−3.1%
(95%
−3.7%
−2.6%)
decrease
2009,
followed
3.4%
increase
1.9%
-4.8%)
2009
2019.
Decreasing
increasing
showed
modestly
different
turning
points
female
(1991-2009,
2009-2019),
White
Hispanic
(1991-2007,
2007-2019),
Black
(1991-2005,
2005-2019)
Although
no
significant
observed
male
(68.4%
increase;
0.2%
-1.2%)
(79.7%
0.1%-1.5%)
had
greater
increases
attempts.
Interaction
revealed
(APC,
4.3%;
1.5%-7.1%),
2005
3.4%;
1.4%-5.4%),
3.3%;
1.0%-5.6%)
3.1%;
0.3%-6.0%).
Conclusions
Relevance
The
findings
this
study
show
apparent
Increases
since
individuals;
represented
largest
Evidence-based
programs
need
be
tailored
calling
diversification
health
care
system,
school,
community
approaches.
American Journal of Psychiatry,
Journal Year:
2022,
Volume and Issue:
179(6), P. 422 - 433
Published: May 23, 2022
Suicide
rates
among
ethnoracially
minoritized
youth
(i.e.,
of
color)
peak
before
the
age
30,
and
striking
disparities
in
access
to
mental
health
services
have
been
identified
this
group.
However,
suicide
prevention
strategies
yet
fully
address
structural
racism
as
a
mechanism
producing
risk,
protective
factors,
quality
effective
intervention
for
color.
Such
an
approach
is
critical
provide
more
culturally
responsive
care.
Through
adapted
socio-ecological
model,
authors
propose
Structural
Racism
Prevention
Systems
Framework
illustrate
pathways
through
which
impacts
color
United
States.
The
contextualize
impact
three
key
settings
where
occurs:
services,
schools,
interface
between
crisis
care
law
enforcement.
posit
that
attention
must
be
paid
intersection
mutually
reinforcing,
interdependent
systems
rather
than
isolation.
then
recommendations
prevention,
including
macro-level
interventions
improve
societal
conditions,
research
inform
solutions,
training
approaches
institutional
racism,
clinical
racial
trauma
on
youths
families.
BMJ,
Journal Year:
2023,
Volume and Issue:
unknown, P. e073591 - e073591
Published: April 12, 2023
Abstract
Bipolar
disorders
(BDs)
are
recurrent
and
sometimes
chronic
of
mood
that
affect
around
2%
the
world’s
population
encompass
a
spectrum
between
severe
elevated
excitable
states
(mania)
to
dysphoria,
low
energy,
despondency
depressive
episodes.
The
illness
commonly
starts
in
young
adults
is
leading
cause
disability
premature
mortality.
clinical
manifestations
bipolar
disorder
can
be
markedly
varied
within
individuals
across
their
lifespan.
Early
diagnosis
challenging
misdiagnoses
frequent,
potentially
resulting
missed
early
intervention
increasing
risk
iatrogenic
harm.
Over
15
approved
treatments
exist
for
various
phases
disorder,
but
outcomes
often
suboptimal
owing
insufficient
efficacy,
side
effects,
or
lack
availability.
Lithium,
first
treatment
continues
most
effective
drug
overall,
although
full
remission
only
seen
subset
patients.
Newer
atypical
antipsychotics
increasingly
being
found
depression;
however,
long
term
tolerability
safety
uncertain.
For
many
with
combination
therapy
adjunctive
psychotherapy
might
necessary
treat
symptoms
different
illness.
Several
classes
medications
treating
predicting
which
medication
likely
tolerable
not
yet
possible.
As
pathophysiological
insights
into
causes
revealed,
new
era
targeted
aimed
at
causal
mechanisms,
they
pharmacological
psychosocial,
will
hopefully
developed.
time
being,
judgment,
shared
decision
making,
empirical
follow-up
remain
essential
elements
care.
This
review
provides
an
overview
features,
diagnostic
subtypes,
major
modalities
available
people
highlighting
recent
advances
ongoing
therapeutic
challenges.
The Lancet Public Health,
Journal Year:
2023,
Volume and Issue:
8(11), P. e868 - e877
Published: Oct. 26, 2023
Deaths
by
suicide
remain
a
major
public
health
challenge
worldwide.
Identifying
and
targeting
risk
factors
for
mortality
is
potential
approach
to
prevention.
We
aimed
summarise
current
knowledge
on
the
range
magnitude
of
individual-level
in
general
population
evaluate
quality
evidence.
Neuropharmacology,
Journal Year:
2022,
Volume and Issue:
218, P. 109219 - 109219
Published: Aug. 14, 2022
The
N-methyl-d-aspartate
receptor
(NMDAR)
antagonist
(R,S)-ketamine
causes
rapid
onset
and
sustained
antidepressant
actions
in
treatment-resistant
patients
with
major
depressive
disorder
(MDD)
other
psychiatric
disorders,
such
as
bipolar
post-traumatic
stress
disorder.
is
a
racemic
mixture
consisting
of
(R)-ketamine
(or
arketamine)
(S)-ketamine
esketamine),
(S)-enantiomer
having
greater
affinity
for
the
NMDAR.
In
2019,
an
esketamine
nasal
spray
by
Johnson
&
was
approved
USA
Europe
depression.
contrast,
increasing
number
preclinical
studies
show
that
arketamine
has
potency
longer-lasting
antidepressant-like
effects
than
rodents,
despite
lower
binding
Importantly,
side
effects,
i.e.,
psychotomimetic
dissociative
abuse
liability,
are
less
those
animals
humans.
An
open-label
study
demonstrated
MDD.
A
phase
2
clinical
trial
MDD
underway.
This
designed
to
review
brief
history
novel
arketamine,
molecular
mechanisms
underlying
its
actions,
future
directions.
article
part
Special
Issue
on
'Ketamine
Metabolites'.
JAMA Psychiatry,
Journal Year:
2022,
Volume and Issue:
79(3), P. 219 - 219
Published: Jan. 19, 2022
Although
suicide
attempts
remain
the
strongest
risk
factor
for
future
suicide,
little
is
known
about
recent
trends
in
prevalence
of
and
factors
past-year
use
services
among
adults
who
attempted
suicide.To
estimate
annual
rates
mental
health
US
from
2008
to
2019.This
nationally
representative
cross-sectional
study
used
National
Survey
Drug
Use
Health
(NSDUH)
through
2019.
Participants
included
noninstitutionalized
civilians
18
years
or
older
(n
=
484
732).
The
overall
per
100
000
general
population
national
2019
were
estimated,
with
defined
as
self-reported
efforts
kill
one's
self
past
12
months.
Subgroup
analyses
also
performed
by
demographic
characteristics
clinical
conditions.
those
reported
then
examined.
Data
analyzed
October
December
2021.Rate
Multivariate-adjusted
logistic
regression
determine
whether
adjusting
sociodemographic
associated
could
account
change
within
period.Of
732
survey
participants,
most
35
younger
(69.8%),
women
(51.8%),
non-Hispanic
White
individuals
(65.7%).
From
2019,
weighted
unadjusted
attempt
rate
increased
481.2
563.9
(odds
ratio
[OR],
1.17
[95%
CI,
1.01-1.36];
P
.04)
remained
significant
after
controlling
(adjusted
OR
[aOR],
1.23
1.05-1.44];
.01).
Rates
particularly
young
aged
25
(aOR,
1.81
1.52-2.16];
<
.001),
1.33
1.09-1.62];
.005),
unemployed
2.22
1.58-3.12];
.001)
never
married
1.60
1.31-1.96];
substances
1.44
1.19-1.75];
.001).
In
multivariate
analyses,
temporal
trend
increasing
even
other
1.36
1.16-1.60];
Several
subgroups
independently
attempts,
especially
serious
psychological
distress
7.51
6.49-8.68];
major
depressive
episodes
2.90
2.57-3.27];
alcohol
disorder
[95%CI,
1.61-2.04];
P<
well
being
divorced
separated
1.65
1.35-2.02];
1.47
1.27-1.70];
identified
Black
1.41
1.24-1.60];
American
Indian
Alaska
Native,
Asian,
Native
Hawaiian
Other
Pacific
Islander
1.56
1.26-1.93];
Among
a
attempt,
there
was
no
likelihood
receiving
substance-related
services.
During
period,
34.8%
45.5%
needing
but
did
not
receive
them,
2019.Although
appear
be
increasing,
has
increased,
suggesting
need
expand
service
accessibility
and/or
acceptability,
population-wide
prevention
efforts.